Filing Details

Accession Number:
0001209191-16-156690
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-12-23 17:11:16
Reporting Period:
2016-12-23
Filing Date:
2016-12-23
Accepted Time:
2016-12-23 17:11:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175505 Five Prime Therapeutics Inc FPRX Pharmaceutical Preparations (2834) 260038620
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1475714 T Lewis Williams Two Corporate Drive
South San Francisco CA 94080
President, Ceo And Chairman Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-12-23 155 $4.56 434,047 No 4 M Direct
Common Stock Acquisiton 2016-12-23 19 $6.89 434,066 No 4 M Direct
Common Stock Acquisiton 2016-12-23 10 $8.49 434,076 No 4 M Direct
Common Stock Acquisiton 2016-12-23 29,816 $5.54 463,892 No 4 M Direct
Common Stock Disposition 2016-12-23 29,700 $50.49 434,192 No 4 S Direct
Common Stock Disposition 2016-12-23 300 $51.02 433,892 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2016-12-23 155 $0.00 155 $4.56
Common Stock Employee Stock Option (right to buy) Disposition 2016-12-23 19 $0.00 19 $6.89
Common Stock Employee Stock Option (right to buy) Disposition 2016-12-23 10 $0.00 10 $8.49
Common Stock Employee Stock Option (right to buy) Disposition 2016-12-23 29,816 $0.00 29,816 $5.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
91,217 2019-04-15 No 4 M Direct
14,438 2020-07-28 No 4 M Direct
16,349 2021-10-19 No 4 M Direct
31,159 2022-07-15 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2016.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.04, inclusive.
  4. This option is fully vested and immediately exercisable.